<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2720">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04383717</url>
  </required_header>
  <id_info>
    <org_study_id>Levamisole and isoprinosine</org_study_id>
    <nct_id>NCT04383717</nct_id>
  </id_info>
  <brief_title>Levamisole and Isoprinosine in the Treatment of COVID19: A Proposed Therapeutic Trial</brief_title>
  <official_title>The Efficacy of Levamisole and Isoprinosine in the Treatment of COVID19: A Proposed Therapeutic Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The use of both levamisole &amp; Isoprinosine has both synergistic and complementary effect in
      the treatment of COVID 19 infection
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study design: Randomized controlled trial, randomization by closed envelope technique
      Informed consent will be written for each patient of either group

      At the beginning of the study all patients will have the following investigations done: CBC
      with differential, ESR, PCR for COVID 19, D dimer and CT chest and confirmed cases will
      included in the study

      Pregnant and lactating women together with children with other comorbidities will be excluded
      from the study

      Study groups:

      Duration of the study is 4 weeks

      Both groups with persistent COVID 19 symptoms that require hospitalization

      Group 1: 30 patients with confirmed COVID19 infection and sharing clinical features like
      fever, malaise, sore throat, runny nose, persistent cough &amp;dyspnea, requiring hospitalization

      Group 2: control group: 30 patients

      Treatment endpoint • Cure of patients: Improvement of symptoms Laboratory findings ESR and
      total leucocytic count returning to normal PCR negative Radiological improvement

      • Worsening of symptoms or fatalities
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 5, 2020</start_date>
  <completion_date type="Anticipated">October 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>COVID 19 induced fever in both groups</measure>
    <time_frame>4 weeks</time_frame>
    <description>Improvement of fever in degrees celsius</description>
  </primary_outcome>
  <primary_outcome>
    <measure>COVID 19 induced dyspnea in both groups</measure>
    <time_frame>4 weeks</time_frame>
    <description>improvement of dyspnea by normalization of respiratory rate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>COVID 19 viral load in both groups</measure>
    <time_frame>4 weeks</time_frame>
    <description>PCR of COVID 19 changes from positive to negative</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>laboratory clearance in both groups: CRP in mg/dL</measure>
    <time_frame>4 weeks</time_frame>
    <description>CRP in mg/dL</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Respiratory Tract Infections</condition>
  <arm_group>
    <arm_group_label>Proposed treatment group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Levamisole and isoprinosine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>hydroxychloroquine and azithromycin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levamisole and isoprinosine</intervention_name>
    <description>oral tablets levamisole 50 mg 3 times daily every other day for 2 weeks Isoprinosine oral tablets 1 g 4 times daily for 2 weeks</description>
    <arm_group_label>Proposed treatment group</arm_group_label>
    <other_name>ketrax and inosiplex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin and hydroxychloroquine</intervention_name>
    <description>oral tablets daily 500 mg azithromycin Oral tablets daily 200 mg hydroxychloroquine twice daily</description>
    <arm_group_label>Control group</arm_group_label>
    <other_name>Zithromax and plaquinel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed COVID 19 infection (positive PCR, elevated ESR, leucopenia)

          -  Clinical picture of COVID 19 infection including fever, malaise, sore throat,
             coughing, dyspnea, and runny nose

        Exclusion Criteria:

          -  Mild cases of COVID 19 that do not require hospitalization

          -  Pregnant &amp; lactating women

          -  Children with other comorbidities

          -  People who received previous treatment for COVID 19 in the last 2 weeks N.B. Diabetes
             and hypertension not excluded
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohamed El Darouti, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cairo University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hagar El Sayed, MD</last_name>
    <phone>0223682030</phone>
    <email>hgr_ntr@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mohamed El Darouti, Professor</last_name>
    <phone>0223682030</phone>
  </overall_contact_backup>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 4, 2020</study_first_submitted>
  <study_first_submitted_qc>May 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 12, 2020</study_first_posted>
  <last_update_submitted>May 11, 2020</last_update_submitted>
  <last_update_submitted_qc>May 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Hagar El Sayed</investigator_full_name>
    <investigator_title>Dermatology Lecturer Cairo University</investigator_title>
  </responsible_party>
  <keyword>Levamisole</keyword>
  <keyword>Isoprinosine</keyword>
  <keyword>COVID19</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Tract Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azithromycin</mesh_term>
    <mesh_term>Hydroxychloroquine</mesh_term>
    <mesh_term>Levamisole</mesh_term>
    <mesh_term>Inosine Pranobex</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

